MedTrace Logo

NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer

NCT03146663 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2021-02-21

Study results available
· View outcomes & findings →

Summary

This study was designed to evaluate the effect of two dose levels of NUC-1031 (500 mg/m2 and 750mg/m2) in patients with ovarian cancer. The primary objective was to determine the anti-tumor activity of NUC-1031 at the selected dose level (500 mg/m2 or 750 mg/m2).

Conditions

Interventions

DRUG

NUC-1031 500 mg

NUC-1031 500 mg/m2 on Days 1, 8, and 15 of a 28-day cycle.

DRUG

NUC-1031 750mg

NUC-1031 750 mg/m2 on Days 1, 8, and 15 of a 28-day cycle

Sponsors & Collaborators

  • NuCana plc

    lead OTHER

Principal Investigators

  • Elisabeth Oelmann, MD PhD · NuCana plc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-28
Primary Completion
2019-12-31
Completion
2019-12-31
FDA Drug
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03146663 on ClinicalTrials.gov